A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

A single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to evaluate the effect of multiple doses of Fluconazole, a CYP3A4 and CYP2C9 inhibitor, on the pharmacokinetics (PK) of CTP-543 in healthy subjects

开始日期2022-07-11

申办/合作机构

Concert Pharmaceuticals, Inc.

NCT05467709

/ Completed临床1期

A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

This is a single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to determine the effect of CTP-543 on the pharmacokinetics (PK) of midazolam in healthy adult subjects

开始日期2022-06-21

申办/合作机构

Concert Pharmaceuticals, Inc.

NCT05467696

/ Completed临床1期

A Phase 1 Open-Label, Two-Period, Two-Treatment, Crossover Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

This is an open-label, single-dose, two period crossover study to evaluate the effect of food on the bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

开始日期2022-06-14

申办/合作机构

Concert Pharmaceuticals, Inc.

100 项与氘代芦可替尼相关的临床结果

登录后查看更多信息

100 项与氘代芦可替尼相关的转化医学

登录后查看更多信息

100 项与氘代芦可替尼相关的专利（医药）

登录后查看更多信息

项与氘代芦可替尼相关的文献（医药）

2025-07-01·AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential

Review

作者: Neubauer, Zachary J K ; Iorizzo, Matilde ; Sechi, Andrea ; Zhou, Maggie ; Lipner, Shari R

BACKGROUND:

Inflammatory nail disorders can have a significant impact on patients' quality of life owing to aesthetic and functional concerns. They are also challenging to treat because the therapeutic armamentarium is quite limited. This systematic review aims to report the efficacy and safety of Janus kinase and Tyrosine kinase 2 inhibitors in treating these conditions.

METHODS:

We conducted a comprehensive search on PubMed, Cochrane, and Embase Library to find eligible case reports, case series, single-arm clinical trials, and randomized controlled trials. We used the following search terms from inception until 15 December, 2024: "nail" AND "jak inhibitors" OR "tofacitinib" OR "baricitinib" OR "abrocitinib" OR "ruxolitinib" OR "deuruxolitinib" OR "upadacitinib" OR "ritlecitinib" OR "deucravacitinib" (nine searches in total).

RESULTS:

Of 441 articles found, 31 were included in this study. The most extensively studied drug was tofacitinib, followed by baricitinib, deucravacitinib, upadacitinib, and abrocitinib. Janus kinase/Tyrosine kinase 2 inhibitors demonstrated improvements in inflammatory nail conditions, with generally mild adverse events (nasopharyngitis and transient laboratory abnormalities being most common). The topical formulation of tofacitinib, the only one studied in these nail diseases, also demonstrated promising results with minimal systemic absorption and no side effects.

CONCLUSIONS:

This review highlights Janus kinase/Tyrosine kinase 2 inhibitors as a valuable addition to the therapeutic arsenal for inflammatory nail disorders while emphasizing the importance of safety assessments and tailored treatment approaches. The long-term safety of Janus kinase/Tyrosine kinase 2 inhibitors still needs further investigation and the potential for adverse events emphasizes the need for tailored therapeutic strategies, including more studies on topical formulations.

2025-06-01·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Most men choose eyebrows versus scalp hair: Response to Mostaghimi et al., “Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata”

Letter

作者: Coppinger, Austin J ; Wambier, Carlos G

2025-06-01·PHARMACOLOGICAL RESEARCH

Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update

Review

作者: Roskoski, Robert

Because of the deregulation of protein kinase action in many inflammatory diseases and cancer, the protein kinase family has become one of the most significant drug targets in the 21st century. There are 85 FDA-approved protein kinase antagonists that target about two dozen different enzymes and four of these drugs were approved in 2024 and a fifth was approved in 2025. Of these drugs, five target dual specificity protein kinases (MEK1/2), fourteen inhibit protein-serine/threonine protein kinases, twenty-one block nonreceptor protein-tyrosine kinases, and 45 target receptor protein-tyrosine kinases. The data indicate that 75 of these drugs are prescribed for the treatment of neoplasms. Seven drugs (abrocitinib, baricitinib, deucravacitinib, deuruxolitinib, ritlecitinib, tofacitinib, upadacitinib) are prescribed for the management of inflammatory diseases (atopic dermatitis, rheumatoid arthritis, psoriasis, alopecia areata, and ulcerative colitis). Of the 85 FDA-approved agents, about two dozen are used in the treatment of multiple diseases. The following four drugs received FDA approval in 2024 - deuruxolitinib (alopecia areata), ensartinib and lazertinib (non-small cell lung cancer), and tovorafenib (pediatric glioma) while mirdametinib was approved in 2025 for the treatment of type I neurofibromatosis (von Recklinghausen disease). Apart from netarsudil, temsirolimus, and trilaciclib, the approved protein kinase blockers are orally bioavailable. This article summarizes the physicochemical properties of all 85 FDA-approved small molecule protein kinase inhibitors including the molecular weight, number of hydrogen bond donors/acceptors, ligand efficiency, lipophilic efficiency, polar surface area, and solubility. A total of 39 of the 85 FDA-approved drugs have a least one Lipinski rule of 5 violation.

139

项与氘代芦可替尼相关的新闻（医药）

2025-07-18

·FiercePharma

Fierce Pharma Asia—China biotech deal boom; Takeda's narcolepsy win; Sino Biopharm's LaNova buyout

Rising biotech deals involving Chinese drugs, Takeda's positive OX2R readouts, and LaNova's acquisition by Sino Biopharm made our news this week. Biotech deals involving assets developed in China are surging, a Jefferies report shows. Takeda is preparing its narcolepsy candidate oveporexton for an FDA filing after two positive phase 3 readouts. Merck & Co.'s PD-1xVEGF partner is being acquired. And more.1. China biotechs ‘reshaping’ US biopharma as outlicensing deals rise 11%: Jefferies reportAbout a third of biopharma’s outlicensing deal value in the first quarter of 2025 centered on Chinese assets, versus 21% during the same period in both 2024 and 2023, according to Jefferies. Since 2022, China biotechs have developed 639 first-in-class drug candidates, a sharp rise compared with prior years, Jefferies tallied.2. Takeda’s narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filingTakeda’s OX2R agonist oveporexton has hit the mark in two phase 3 narcolepsy trials. The FirstLight and RadiantLight trials met their primary endpoints showing statistically significant improvements for the drug compared with placebo in excessive daytime sleepiness, as measured by the Maintenance of Wakefulness Test at week 12. The company is now preparing for an FDA approval filing.3. Sino Biopharm buys Merck's PD-1xVEGF bispecific partner LaNova for up to $951MLaNova Medicines, from which Merck & Co. recently licensed a PD-1xVEGF bispecific candidate, is being bought out by Chinese compatriot Sino Biopharmaceutical in a deal worth up to $951 million. In addition, LaNova also provided AstraZeneca with a GPRC5D-targeting antibody-drug conjugate. Before the LaNova transaction, very few, if any, Chinese pharmas have acquired innovative domestic biotechs.4. For Lundbeck and Otsuka's PTSD filing, FDA questions Rexulti efficacy after failed phase 3For an upcoming advisory committee meeting, the FDA flagged “discordant results” from two phase 3 trials that Lundbeck and Otsuka are using in their application for Rexulti, in combination with Viatris’ Zoloft, as a treatment for post-traumatic stress disorder. The FDA is asking experts to weigh in on whether an exploratory phase 2 study can overcome one negative phase 3.5. Otsuka inks $613M deal for Swedish biotech's autoimmune antibodiesOtsuka is paying $33 million upfront for Cantargia’s IL1RAP antibody, CAN10, as well as a backup candidate, against autoimmune and inflammatory disorders. The deal also includes up to $580 million in milestone payments and gives the Japanese drugmaker exclusive first rights of negotiation for Cantargia’s next-gen IL1RAP programs.6. Sun Pharma's alopecia med Leqselvi hits US market after Incyte patent settlementSun Pharma has reached a patent settlement with Incyte so the Indian company can launch its JAK inhibitor Leqselvi in the U.S. for severe alopecia areata. Sun will pay an undisclosed upfront payment plus royalty payments until the related patents expire. The deal ended a lawsuit in which Incyte claimed that Leqselvi would infringe on patents around its blockbuster ruxolitinib.7. FDA hands down citations to 3 drugmakers after inspections found contamination, testing concernsMeanwhile, a Sun Pharma plan in Gujarat, India was subject to a 19-page, eight-observation Form 483 following an FDA inspection in June. Some citations, such as “poor aseptic behavior and inadequate environmental monitoring,” had previously been flagged in an FDA warning letter in 2022. Separately, a Daewoo Pharm site in Busan, Korea, and a Glenmark facility in Madhya Pradesh, India, received FDA warning letters.Other News of Note:8. Astellas reports 22% sales bump for Izervay, expects trend to continue this year9. China sentences Astellas exec to 3.5 years in prison for espionage (Bloomberg)10. Hengrui's GLP-1/GIP agonist reports 18% weight loss in phase 3 trial, readies China push11. Acumen taps JCR’s blood-brain barrier tech for $555M Alzheimer’s deal12. GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment13. Kowa licenses Nicox’s intraocular pressure eye drop for up to €191.5M (release)14. Korea’s Illimis raises $42M series B to advance Alzheimer’s candidate (release)

临床3期并购

2025-07-18

·PRNewswire

Weekly Recap: 14 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a breakthrough in dental manufacturing, a new alopecia treatment and an app to help women navigate perimenopause. NEW YORK, July 18, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, July 14-18, 2025. Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions The proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs. Cardinal Health announces One Voice Initiative to support independent pharmacy advocacy This investment furthers Cardinal Health's longstanding advocacy around the future of independent pharmacies and ongoing partnerships with industry organizations to support pharmacists' efforts to build relationships with elected officials at all levels of government.  Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata LEQSELVI demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by Week 24. Some patients (3%) achieved 80% or more scalp coverage as fast as 8 weeks. Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing The transaction will bring together complementary technologies to serve high-volume testing in attractive and regulated end-markets. The combined company will have best-in-class liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions, doubling Waters' total addressable market to approximately $40 billion. Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform The proceeds will be used to accelerate the development of GAIA-based Alzheimer's Disease therapeutics, expand its target indications to various immune disorders, and broaden its pipeline of potential blockbuster drug candidates. The company is actively pursuing early-stage collaborations with global pharmaceutical companies and research institutions to add value to internal programs. Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa If approved, MCO-010 has the potential to be the standard of care for retinitis pigmentosa, delivered via a one-time, in-office intravitreal injection with the ability to restore vision in patients with severe vision loss regardless of their underlying genetic mutation. OpenEvidence, the Fastest-Growing Application for Physicians in History, Announces $210 Million Round at $3.5 Billion Valuation OpenEvidence rapidly surfaces relevant medical knowledge, synthesizes medical research, and gives clinicians the power to make faster, more evidence-based decisions—accelerating both medical literature review and clinical decision support. By reducing the lag between new evidence and bedside application, OpenEvidence enables improved patient outcomes. Flo for Perimenopause is Launching to Empower the 1 Billion+ Women Who Experience Perimenopause Without the Support They Deserve The in-app feature offers educational content that is backed by research and insights, and created in collaboration with a team of 100+ medical experts. With Flo for Perimenopause, Flo Health is redefining how women navigate one of the most misunderstood and underserved stages of life. Akeso Announces First Patient Enrolled in the Phase III Trial (AK112-312/HARMONi-GI6) of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer Colorectal cancer remains the third most common cancer globally and the second leading cause of cancer-related deaths. In 2022, over 1.9 million new cases were reported, with approximately 904,000 deaths. Of these, about 95% of mCRC cases are classified as microsatellite stable (MSS) or proficient mismatch repair (pMMR), which traditionally show poor responses to immunotherapy and the tumors are often referred to as an "immune desert." HeyGears Achieves Breakthrough in Multi-Material Resin 3D Printing, Overcoming Bottlenecks in Dental Manufacturing HeyGears' biocompatible photopolymer resin materials and high-precision 3D printing solutions ensure the quality and reliability of the results. AI-powered digital workflows optimize every step, from model design to post-processing, achieving highly efficient and intelligent large-scale dental production. SandboxAQ and iOncologi Partner to Accelerate Brain Cancer Treatment with AI-driven Drug Discovery For Glioblastoma "Our collaboration with iOncologi aims to create a new and effective treatment for this challenging condition, pairing the most comprehensive oncology datasets with advanced quantitative AI tools and simulation techniques, greatly accelerating the drug discovery process," said Jack Hidary, CEO of SandboxAQ. Edgepark expands diabetes offerings with two new product innovations "Diabetes is one of the fastest-growing conditions in the United States, and the introduction of innovations like a one-year wearable system and blood glucose biosensors that can be used without a prescription will no doubt play a pivotal role in the well-being of the patients we serve," said Anthony Alvarez, SVP and GM of Edgepark. Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora This new agreement expands Citius Oncology's commercial distribution network, providing additional access and product availability upon launch. The agreement with Cencora, a leader in specialty pharmaceutical distribution and services, builds on a previously announced distribution services agreement to support long-term scalability and market reach of LYMPHIR. Viome and Scripps Research Partner to Develop First At-home RNA Screening Test to Prevent Colon Cancer Before It Strikes Scripps Research and Viome will conduct the observational clinical study in a cohort of healthy patients undergoing routine gastrointestinal exams. Leveraging Viome's RNA sequencing and AI platform, trained on the world's largest gene expression database, the test seeks to identify molecular signals years before standard screenings. For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

并购临床3期

2025-07-17

·药事纵横

JAK抑制剂新上市！专治“寸草不生”

2025年7月14日，印度太阳制药（Sun Pharmaceutical Industries Limited）宣布，其治疗重度斑秃的新药LEQSELVI™（deuruxolitinib）8mg片剂已正式在美国上市，供医疗服务提供者和重度斑秃患者使用。该药适用于治疗成人重度斑秃，为这一疾病领域带来了全新的治疗选择。斑秃是一种自身免疫性疾病，免疫系统攻击毛囊，导致头皮和身体毛发部分或全部脱落。头皮是最常见的受累部位，但任何有毛发的部位都可能单独或与头皮同时受累。该疾病可终生发病，男性和女性均可发病。斑秃可能与严重的心理后果相关，包括焦虑和抑郁。Leqselvi是一种每天两次口服选择性Janus激酶(JAK)JAK1和JAK2抑制剂，旨在阻断Janus激酶(JAK)。这两种酶在严重斑秃的发病机制中起着关键作用。通过破坏这些通路，Leqselvi旨在阻止脱发进展并促进头发再生。该药获批用于治疗成人重度斑秃（头皮毛发脱落至少50%）是基于两项3期临床试验的积极结果：THRIVE-AA1(NCT04518995)和THRIVE-AA2(NCT04797650)。两项随机、双盲、安慰剂对照临床试验共纳入1223名18-65岁的重度斑秃患者（头皮脱发面积≥50%），评估了服药24周后的头皮毛发再生情况。结果显示，约三分之一的患者在24周时几乎恢复全部头发，3%的患者甚至在8周内就实现了80%以上的头皮覆盖率。这些数据充分证明了LEQSELVI™疗效显著且起效迅速。作为一种口服JAK1和JAK2抑制剂，LEQSELVI的推荐剂量为8mg，每日两次，可与食物同服或空腹服用。如果出现严重感染或血液学异常，可能需要中断治疗。在开始使用Leqselvi治疗之前，建议进行评估和免疫接种。需注意，该药禁用于CYP2C9慢代谢者及正在服用中强效CYP2C9抑制剂的患者，也不建议与其他JAK抑制剂、生物免疫调节剂等联用。其潜在风险包括严重感染、恶性肿瘤、心血管事件、血栓、胃肠道穿孔等，用药前需进行结核病筛查、CYP2C9基因型检测及血常规检查等。常见不良反应包括头痛、痤疮、鼻咽炎等。在医学领域，斑秃一直是个棘手的难题。它是一种自身免疫性疾病，免疫系统会错误地将毛囊当作敌人进行攻击，导致局部或广泛的脱发。在过去很长一段时间里，医学界始终没有找到有效的系统性治疗方案，直到JAK抑制剂出现，才为斑秃的治疗带来了新的希望。基于突破性的临床成果，Baricitinib于2022年6月获得FDA批准用于治疗严重斑秃成人患者，成为FDA批准的首个用于治疗斑秃的系统性疗法，其后，FDA于2023年6月批准Ritlecitinib上市，用于治疗12岁以上严重斑秃患者，这也是FDA首次批准用于重度斑秃青少年（12+）患者的治疗药物。从全球研发态势来看，斑秃治疗领域从2024年便迎来快速发展期。根据公开信息，全球约有70款在研新药处于不同开发阶段，其中多款已进入临床试验。这些在研药物的作用靶点也呈现出多元化趋势：除JAK靶点外，针对S1PR家族、OX40、LILRA4等创新靶点的探索，正在不断拓展临床治疗选择。相信在未来会有更多的创新药落地，为更多斑秃患者重拾健康与自信。Ref:https://www.prnewswire.com/news-releases/us-fda--approves-leqselvi-deuruxolitinib-an-oral-jak-inhibitor-for-the-treatment-of-severe-alopecia-areata-302207222.html药事纵横投稿须知：稿费已上调，欢迎投稿

上市批准临床3期突破性疗法临床结果

100 项与氘代芦可替尼相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
斑秃	美国	Sun Pharmaceutical Industries, Inc.	2024-07-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04797650 \| NCT04518995 (AA-2, FDA_CDER) 人工标引	临床3期	斑秃	1,209	Placebo twice daily (Trial AA-1)	獵鏇築鏇膚餘窪壓艱壓(繭窪築鹽廠醖鏇夢窪構) = 窪夢艱艱築願廠衊齋醖齋醖襯鹹網遞壓餘鏇鑰 (觸築夢簾鹽淵蓋鑰築襯 ) 更多	积极	2024-07-25
				LEQSELVI 8 mg twice daily (Trial AA-1)	獵鏇築鏇膚餘窪壓艱壓(繭窪築鹽廠醖鏇夢窪構) = 遞築積鹹廠窪淵鹹鹹鑰齋醖襯鹹網遞壓餘鏇鑰 (觸築夢簾鹽淵蓋鑰築襯 ) 更多
NCT04797650 (THRIVE-AA2, EADV2023)	临床3期	斑秃	517	Deuruxolitinib 8 mg BID	構廠艱觸憲鏇網衊壓築(願夢鏇獵醖壓鹽願鑰築) = 積衊廠鏇構鹹衊齋鑰顧齋鹹醖壓衊餘衊鏇淵鏇 (簾獵鑰積鑰廠鹹繭壓糧 )	积极	2023-10-11
				Deuruxolitinib 12 mg BID	構廠艱觸憲鏇網衊壓築(願夢鏇獵醖壓鹽願鑰築) = 膚願顧鹽觸鹹網夢鬱餘齋鹹醖壓衊餘衊鏇淵鏇 (簾獵鑰積鑰廠鹹繭壓糧 )
NCT04797650 (AA-2 \| THRIVE-AA2, CTgov)	临床3期	斑秃	517	CTP-543 matching placebo (Placebo)	顧夢衊遞鏇遞觸襯醖網 = 襯鬱鑰願鹽觸範鹽鹽淵夢範積築積築鏇衊鬱範 (醖蓋鏇襯構願襯鹹簾壓, 蓋夢廠蓋蓋淵膚襯願壓 ~ 製鹽壓膚鬱鬱鹽鹹膚築) 更多	-	2023-07-03
				CTP-543 (CTP-543 8 mg BID)	顧夢衊遞鏇遞觸襯醖網 = 餘糧夢鬱願蓋蓋餘襯淵夢範積築積築鏇衊鬱範 (醖蓋鏇襯構願襯鹹簾壓, 壓襯醖襯選膚鏇餘築憲 ~ 繭網鹹襯蓋鹹觸願築壓) 更多
NCT04518995 (AA-1 \| THRIVE-AA1, CTgov)	临床3期	斑秃	706	CTP-543 matching placebo (Placebo)	繭艱窪壓憲衊夢築艱鹽 = 餘網廠壓壓鬱糧糧積鏇願製選積鬱積鬱夢鹽襯 (製醖艱範廠憲鏇鏇觸憲, 繭鑰製鹽艱積繭願憲繭 ~ 憲簾衊鹽顧糧壓選憲窪) 更多	-	2023-05-03
				CTP-543 (CTP-543 8 mg BID)	繭艱窪壓憲衊夢築艱鹽 = 獵網鑰遞膚艱鬱構鑰蓋願製選積鬱積鬱夢鹽襯 (製醖艱範廠憲鏇鏇觸憲, 齋顧夢觸窪範網網艱鏇 ~ 淵構夢鑰範襯觸壓鹹齋) 更多
NCT03941548 (CTgov)	临床2期	斑秃	66	CTP-543 Matching Placebo+CTP-543 (CTP-543 12 mg BID)	簾鑰鹹築積壓窪壓衊壓(淵構夢壓醖簾糧範衊衊) = 醖齋鑰願糧蓋艱製膚壓鑰遞獵遞網醖獵壓積憲 (繭糧鹽夢餘繭壓製觸鹽, 34.747) 更多	-	2023-04-05
				CTP-543 Matching Placebo+CTP-543 (CTP-543 24 mg QD)	簾鑰鹹築積壓窪壓衊壓(淵構夢壓醖簾糧範衊衊) = 選網餘鑰壓願廠繭願構鑰遞獵遞網醖獵壓積憲 (繭糧鹽夢餘繭壓製觸鹽, 37.887) 更多
NCT04518995 (THRIVE-AA1, AAD2023)	临床3期	斑秃	706	Placebo	齋積遞製製鹽餘鏇築鬱(顧鹽壓積鏇醖壓鹽醖齋) = 顧製鏇選簾簾網廠範齋築範鏇繭遞膚顧壓襯膚 (廠築鹹顧廠鹹醖範壓膚 )	-	2023-03-17
				CTP-543 8 mg BID	齋積遞製製鹽餘鏇築鬱(顧鹽壓積鏇醖壓鹽醖齋) = 憲蓋鑰鏇憲獵積遞廠獵築範鏇繭遞膚顧壓襯膚 (廠築鹹顧廠鹹醖範壓膚 )
NCT03811912 (CTgov)	临床2期	斑秃	57	CTP-543 Matching Placebo+CTP-543 (CTP-543 8 mg BID)	鹽窪淵齋鹽製鑰糧餘齋(壓淵鏇觸窪範壓齋憲衊) = 壓繭醖鏇繭製遞淵糧淵餘艱餘範醖醖鹽選積築 (積選願淵窪構繭淵鑰窪, 38.21) 更多	-	2022-12-09
				CTP-543 Matching Placebo+CTP-543 (CTP-543 16 mg QD)	鹽窪淵齋鹽製鑰糧餘齋(壓淵鏇觸窪範壓齋憲衊) = 衊夢壓艱糧廠鹽顧鬱鹹餘艱餘範醖醖鹽選積築 (積選願淵窪構繭淵鑰窪, 32.32) 更多
NCT04518995 (THRIVE-AA1, EADV2022)	临床3期	斑秃	706	CTP-543 8 mg BID	淵顧窪觸鹹鑰餘蓋積觸(積繭觸鹽範積鏇選製餘) = 鹽繭憲蓋淵餘顧鹹鹹鬱顧夢淵襯繭鬱艱簾糧製 (觸醖積蓋遞衊積顧醖網, <0.0001) 更多	积极	2022-09-07
				CTP-543 12 mg BID	淵顧窪觸鹹鑰餘蓋積觸(積繭觸鹽範積鏇選製餘) = 蓋鑰鏇觸獵齋糧獵窪鹽顧夢淵襯繭鬱艱簾糧製 (觸醖積蓋遞衊積顧醖網, <0.0001) 更多
NCT03137381 (CTgov)	临床2期	斑秃	149	CTP-543 matching placebo (Combined Placebo)	願簾廠憲鬱鑰範糧膚齋 = 憲壓構鹹鹽顧獵醖簾願夢夢網鏇餘積簾糧鏇廠 (糧夢壓繭繭鏇築繭餘窪, 築淵遞獵獵選廠築鹹繭 ~ 襯憲鹹膚鑰壓窪遞蓋鑰) 更多	-	2022-07-19
				CTP-543 (Cohort 1: CTP-543 4 mg BID)	願簾廠憲鬱鑰範糧膚齋 = 簾鬱積網願範餘蓋蓋艱夢夢網鏇餘積簾糧鏇廠 (糧夢壓繭繭鏇築繭餘窪, 鏇壓鏇積糧壓築糧壓選 ~ 廠積淵夢餘構獵憲觸繭) 更多
NCT03137381 (BusinessWire) 人工标引	临床2期	斑秃	104	ctp-543	齋廠憲淵蓋鏇鬱鹹範鑰(醖製積襯願餘餘範糧鏇) = 蓋鑰窪選願鏇艱壓艱繭積壓網觸積積獵餘範齋 (構觸範窪壓廠鏇襯窪製 )	积极	2019-03-01
				Placebo	齋廠憲淵蓋鏇鬱鹹範鑰(醖製積襯願餘餘範糧鏇) = 繭衊餘齋襯鏇鏇範鏇繭積壓網觸積積獵餘範齋 (構觸範窪壓廠鏇襯窪製 )